AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,190.00p
   
  • Change Today:
    162.00p
  • 52 Week High: 12,404.00p
  • 52 Week Low: 9,501.00p
  • Currency: UK Pounds
  • Shares Issued: 1,550.24m
  • Volume: 3,914,230
  • Market Cap: £188,974m
  • RiskGrade: 123

AstraZeneca's Lynparza approved in Japan

By Frank Prenesti

Date: Thursday 25 Aug 2022

LONDON (ShareCast) - (Sharecast News) - AstraZeneca and MSD's Lynparza has been approved in Japan for the treatment of patients with BRCA-mutated (BRCAm), HER2-negative early breast cancer at high risk of recurrence, the companies said on Thursday.
The approval by Japan's Ministry of Health, Labour, and Welfare was based on results from the OlympiA Phase III trial.

In the trial, Lynparza demonstrated a "statistically significant and clinically meaningful improvement" in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences, new cancers, or death by 42% versus a placebo.

Lynparza also demonstrated a statistically significant and clinically meaningful improvement in overall survival, reducing the risk of death by 32% versus placebo, AstraZeneca said in a statement.

Reporting by Frank Prenesti at Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,190.00p
Change Today 162.00p
% Change 1.35 %
52 Week High 12,404.00p
52 Week Low 9,501.00p
Volume 3,914,230
Shares Issued 1,550.24m
Market Cap £188,974m
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
92.08% below the market average92.08% below the market average92.08% below the market average92.08% below the market average92.08% below the market average
92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average92.16% below the sector average
Price Trend
58.10% above the market average58.10% above the market average58.10% above the market average58.10% above the market average58.10% above the market average
74.07% above the sector average74.07% above the sector average74.07% above the sector average74.07% above the sector average74.07% above the sector average
Income
90.94% below the market average90.94% below the market average90.94% below the market average90.94% below the market average90.94% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Growth
82.55% above the market average82.55% above the market average82.55% above the market average82.55% above the market average82.55% above the market average
94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average94.29% above the sector average

What The Brokers Say

Strong Buy 9
Buy 15
Neutral 5
Sell 0
Strong Sell 1
Total 30
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 22-Feb-24 10-Aug-23
Paid 25-Mar-24 11-Sep-23
Amount 197.00¢ 93.00¢

Trades for 31-May-2024

Time Volume / Share Price
16:52 5,040 @ 12,038.01p
16:51 294 @ 12,190.00p
16:51 378 @ 12,190.00p
16:51 378 @ 12,190.00p
16:51 294 @ 12,190.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page